On Friday, Sagimet Biosciences, a clinical-stage biopharmaceutical company, filed with the SEC to raise up to $75 million in an initial public offering for the second time. It had previously filed in April 2021 to raise $75 million before withdrawing in March 2022. The company is focused on developing novel therapeutics called fatty acid synthase (FASN) inhibitors targeting dysfunctional metabolic pathways in diseases. The lead drug candidate, denifanstat, is an oral, once-daily pill and selecti
Ocean Biomedical (NASDAQ: OCEA) Extends Patent Rights for Breakthrough Idiopathic Pulmonary Fibrosis Discovery To Europe streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
The 52-week results of the phase 3 MAESTRO-NASH trial show promise for resmetirom. One expert called the trial results real game-changer in the field of fatty liver disease. ยง
People with signs of the most advanced liver disease should see a hepatologist, experts say, while primary care clinicians can effectively treat lower-risk cases.
– 6 Oral Presentations and 28 Posters Across HDV, HCV, HBV, NASH and PSC Highlight Progress and Gilead’s Leadership in Addressing Unmet Needs for People Affected by Liver Disease. | June 14, 2023